Stevanato

Stevanato, a Pharmaceutical Preparation Manufacturing company headquartered in Italy, reported its total greenhouse gas emissions for 2025 as approximately 769.6 million kg CO2e. This includes about 54.7 million kg CO2e from Scope 1 emissions, approximately 35.4 million kg CO2e from market-based Scope 2 emissions, and around 679.6 million kg CO2e from Scope 3 emissions.

For 2024, Stevanato's total emissions were approximately 723.1 million kg CO2e, with Scope 1 emissions at roughly 48.3 million kg CO2e, market-based Scope 2 emissions at about 61.9 million kg CO2e, and Scope 3 emissions totalling around 612.9 million kg CO2e.

Looking back to 2023, Stevanato reported Scope 1 emissions of approximately 45.5 million kg CO2e and market-based Scope 2 emissions of about 49 million kg CO2e. There is no Scope 3 data available for 2023. In 2022, Scope 1 emissions were around 44.3 million kg CO2e, and market-based Scope 2 emissions were approximately 55.9 million kg CO2e. For 2021, Scope 1 emissions stood at roughly 43.6 million kg CO2e, and market-based Scope 2 emissions were about 47.6 million kg CO2e.

Stevanato is committed to achieving Net Zero by 2050, with both near-term and long-term Science Based Targets (SBTs) in place. The company, via its relation to STV (the S&P Global name for the source organization, based on the SBTi data), has committed to reducing absolute Scope 1 and Scope 2 GHG emissions by 65.0% by 2035, using 2023 as a base year. Furthermore, it aims to reduce Scope 3 GHG emissions by 67.0% per USD value added within the same timeframe. These targets are consistent with reductions required to keep warming to 1.5°C. Stevanato's emissions data and climate commitments are cascaded from its parent company, Stevanato Group S.p.A.